MEIP Read Out Pracinostat

MEI Pharma Reports Significant Clinical Activity in Phase II Study of Pracinostat in Front Line Acute Myeloid Leukemia

80% 胜算!

"Based on these encouraging data and recent discussions with the U.S. Food and Drug Administration, we are now actively preparing for a Phase III registration study using CR as the primary endpoint to support accelerated approval for this indication and overall survival as the endpoint for full approval," said Robert D. Mass, MD, Chief Medical Officer of MEI Pharma. "Meanwhile, we look forward to unblinding our randomized, placebo-controlled Phase II study of Pracinostat and azacitidine in front line myelodysplastic syndrome and reporting top line data in March 2015."
博主已关闭评论